Geneva, March 20 -- International Clinical Trials Registry received information related to the study (CTRI/2026/02/0104945) titled 'Open-label Extension of KarXT and KarX EC for Agitation in Alzheimer Disease' on Feb. 26.
Study Type: Interventional
Study Design:
Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Open Label
Primary Sponsor: Bristol Myers Squibb India Private Limited
Condition:
Health Condition 1: G301- Alzheimers disease with late onset
Intervention:
Intervention1: Drug or Xanomeline Enteric Capsule: KarX-EC BMS986519 - 2 Bottles (KarXTor PBO and KarX-EC or PBO) will b...